Limosilactobacillus reuteri - BioGaia/Infant Bacterial Therapeutics
Alternative Names: Apylori Probiotic Capsules; BioGaia ProTectis; IBP 9414; Lactobacillus reuteri; Lactobacillus reuteri ATCC 55730; Lactobacillus reuteri DSM 17938; Lactobacillus reuteri Protectis; NEC therapy - BioGaiaLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator BioGaia; Infant Bacterial Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Bacteria; Laxatives; Probiotics
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gastrointestinal disorders
- Phase III Necrotising enterocolitis
- Phase II Constipation; Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal-disorders(In volunteers) in Sweden (PO, Capsule)
- 16 Jun 2023 European Patent Office approves patent application for Lactobacillus reuteri related to IBP 9414
- 16 Jun 2023 Infant Bacterial Therapeutics plans to launch IBP 9414 in Europe